Researchers use skin cells from pediatric patients and program them into stem cells to investigate molecular mechanisms for rare form of childhood leukemia
Juvenile myelomonocytic leukemia (JMML) is diagnosed in children whose average age at diagnosis is two. Hematopoietic stem cell transplantation can cure some patients but not all. On the other end, minimal treatment -- or none at all -- can also result in remission. How does one decide how to treat JMML patients?